- Zimmer Biomet (ZBH, Financial) appoints Kevin Thornal as Group President for Global Businesses and the Americas, effective July 1, 2025.
- Thornal brings over 20 years of experience in the medical technology sector, including leadership roles at Nevro Corp., Hologic, and Stryker Corp.
- Thornal has a proven track record of delivering sustained double-digit growth in previous positions.
Zimmer Biomet Holdings, Inc. (ZBH), a leader in global medical technology, announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas, effective July 1, 2025. Thornal will report to Chairman-Elect, President and CEO Ivan Tornos, overseeing the Americas commercial organization and driving the business strategy for global Knees, Hips, S.E.T., and Data, Technology, and Enabling Solutions units.
Kevin Thornal brings over two decades of expertise in the medical technology, orthopedics, and diagnostics industries. Prior to joining Zimmer Biomet, he served as CEO and President of Nevro Corp. Thornal’s career includes significant achievements at Hologic, Inc., where he led the Global Diagnostic Solutions division to double-digit growth during the COVID-19 pandemic, and Stryker Corp., where he managed North American sales for the Interventional Spine business, achieving sustained growth.
In a statement, Ivan Tornos expressed confidence in Thornal’s ability to enhance Zimmer Biomet’s performance and commercial execution: “Kevin is an incredible addition to our leadership team at an exciting time for our Company. His expertise and drive to win will advance our mission of alleviating pain and improving the quality of life worldwide.”
Thornal will officially assume his role at Zimmer Biomet on July 1, 2025, and looks forward to contributing to the company’s culture of collaboration and innovation, with a focus on meeting unmet needs in musculoskeletal health through the company’s innovative product pipeline.
